<DOC>
	<DOCNO>NCT00432627</DOCNO>
	<brief_summary>This study ass pharmacokinetics deferasirox hepatically impaired patient compare healthy volunteer .</brief_summary>
	<brief_title>Impact Hepatic Impairment Pharmacokinetics Deferasirox .</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criterion hepatic impairment : Physical sign consistent clinical diagnosis liver cirrhosis ChildPugh Clinical Assessment Score consistent degree hepatic impairment Otherwise consider healthy Inclusion criterion healthy volunteer : â€¢ In good health . Exclusion criterion hepatic impairment : Clinically significant abnormal finding hepatic impairment Clinical evidence severe ascites History surgical portosystemic shunt Any evidence progressive liver disease within last 4 week Exclusion criterion healthy control : Clinical evidence liver disease liver injury A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result Use prescription medication within 1 month prior dose Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>adult</keyword>
	<keyword>deferasirox</keyword>
</DOC>